Phosphodiesterase-2 is up-regulated in human failing hearts and blunts β-adrenergic responses in cardiomyocytes.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Journal of the American College of Cardiology

• Publication date

  2013-10-22

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.jacc.2013.05.057PMID 23810893
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• PDEs create local domains of cAMP signaling.

  2012cited by this paper
• Reorganized PKA-AKAP associations in the failing human heart.

  2012cited by this paper
• Phosphodiesterases and cyclic GMP regulation in heart muscle.

  2012cited by this paper
• Compartmentation of Cyclic Nucleotide Signaling in the Heart: The Role of Cyclic Nucleotide Phosphodiesterases

  2012influential reference
• cGMP Signals Modulate cAMP Levels in a Compartment-Specific Manner to Regulate Catecholamine-Dependent Signaling in Cardiac Myocytes

  2011cited by this paper
• Mammalian cyclic nucleotide phosphodiesterases: molecular mechanisms and physiological functions.

  2011cited by this paper
• Constitutively active phosphatase inhibitor-1 improves cardiac contractility in young mice but is deleterious after catecholaminergic stress and with aging.

  2010cited by this paper
• Ventricular Phosphodiesterase-5 Expression Is Increased in Patients With Advanced Heart Failure and Contributes to Adverse Ventricular Remodeling After Myocardial Infarction in Mice

  2009cited by this paper
• β-Adrenergic stimulation and myocardial function in the failing heart

  2009cited by this paper
• Decreased Expression and Activity of cAMP Phosphodiesterases in Cardiac Hypertrophy and Its Impact on &bgr;-Adrenergic cAMP Signals

  2009cited by this paper
• Phosphatase inhibitor-1-deficient mice are protected from catecholamine-induced arrhythmias and myocardial hypertrophy.

  2008cited by this paper
• cAMP and cGMP Signaling Cross-Talk Role of Phosphodiesterases and Implications for Cardiac Pathophysiology

  2007influential reference
• Compartmentalized Phosphodiesterase-2 Activity Blunts &bgr;-Adrenergic Cardiac Inotropy via an NO/cGMP-Dependent Pathway

  2006cited by this paper
• Compartmentation of cyclic nucleotide signaling in the heart: the role of cyclic nucleotide phosphodiesterases.

  2006cited by this paper
• Differential Effects of cGMP Produced by Soluble and Particulate Guanylyl Cyclase on Mouse Ventricular Myocytes

  2005cited by this paper
• Functional Role of Phosphodiesterase 3 in Cardiomyocyte Apoptosis: Implication in Heart Failure

  2005cited by this paper
• Antihypertrophic actions of the natriuretic peptides in adult rat cardiomyocytes: importance of cyclic GMP.

  2003cited by this paper
• GAF domains: two-billion-year-old molecular switches that bind cyclic nucleotides.

  2002cited by this paper
• Inhibition of calcineurin-NFAT hypertrophy signaling by cGMP-dependent protein kinase type I in cardiac myocytes

  2002cited by this paper
• Cyclic GMP regulation of the L‐type Ca2+ channel current in human atrial myocytes

  2001cited by this paper
• Local response of L‐type Ca2+ current to nitric oxide in frog ventricular myocytes

  2001cited by this paper
• β-Adrenergic Receptor Blockade in Chronic Heart Failure

  2000cited by this paper
• beta-adrenergic receptor blockade in chronic heart failure.

  2000cited by this paper
• Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)

  1999cited by this paper
• cGMP-stimulated cyclic nucleotide phosphodiesterase regulates the basal calcium current in human atrial myocytes.

  1997influential reference
• Structure, Localization, and Regulation of cGMP-inhibited Phosphodiesterase (PDE3)*

  1997influential reference
• The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.

  1996cited by this paper
• Erythro-9-(2-hydroxy-3-nonyl)adenine inhibits cyclic GMP-stimulated phosphodiesterase in isolated cardiac myocytes.

  1995cited by this paper
• Nitric oxide regulates cardiac Ca2+ current. Involvement of cGMP-inhibited and cGMP-stimulated phosphodiesterases through guanylyl cyclase activation.

  1993cited by this paper
• Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group.

  1991cited by this paper
• High concentrations of a cGMP-stimulated phosphodiesterase mediate ANP-induced decreases in cAMP and steroidogenesis in adrenal glomerulosa cells.

  1991cited by this paper
• Opposite effects of cyclic GMP and cyclic AMP on Ca2+ current in single heart cells

  1986cited by this paper
• Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts.

  1982cited by this paper

• Cyclic nucleotide phosphodiesterases as drug targets.

  2025cites this paper
• Cardiac Gene Therapy With Phosphodiesterase 2A Limits Remodeling and Arrhythmias in Mouse Models of Heart Failure

  2025cites this paper
• Bayliss Starling Prize Lecture 2023: Neuropeptide‐Y being ‘unsympathetic’ to the broken hearted

  2024cites this paper
• Gene therapy with phosphodiesterases 2A and 4B ameliorates heart failure and arrhythmias by improving subcellular cAMP compartmentation.

  2024cites this paper
• Exploring the mechanisms underlying effects of bisphenol a on cardiovascular disease by network toxicology and molecular docking

  2024cites this paper
• Nanodomain cAMP signalling in cardiac pathophysiology: potential for developing targeted therapeutic interventions.

  2024cites this paper
• [Cyclic nucleotide phosphodiesterases: therapeutic targets in cardiac hypertrophy and failure].

  2024cites this paper
• Intertwined regulators: hypoxia pathway proteins, microRNAs, and phosphodiesterases in the control of steroidogenesis

  2024cites this paper
• Abnormal phosphorylation / dephosphorylation and Ca2+ dysfunction in heart failure

  2024cites this paper
• Cardiac cGMP Regulation and Therapeutic Applications

  2024cites this paper
• Phosphodiesterases type 2, 3 and 4 promote vascular tone in mesenteric arteries from rats with heart failure.

  2023cites this paper
• Clinical pharmacology of cardiac cyclic AMP in human heart failure: too much or too little?

  2023cites this paper
• OR-1896 increases force of contraction in the isolated human atrium

  2023cites this paper
• CRISPR/Cas9 Knock-Out in Primary Neonatal and Adult Cardiomyocytes Reveals Distinct cAMP Dynamics Regulation by Various PDE2A and PDE3A Isoforms

  2023cites this paper
• Cardiac RGS Proteins in Human Heart Failure and Atrial Fibrillation: Focus on RGS4

  2023cites this paper
• Regulation of cardiac function by cAMP nanodomains

  2023cites this paper
• CNP Promotes Antiarrhythmic Effects via Phosphodiesterase 2

  2023cites this paper
• Phosphodiesterase in heart and vessels: from physiology to diseases

  2023cites this paper
• Multimodal characterization of dilated cardiomyopathy: Geno‐ And Phenotyping of PrImary Cardiomyopathy (GrAPHIC)

  2023cites this paper
• Natriuretic Peptide Receptor B Protects Against Atrial Fibrillation by Controlling Atrial cAMP Via Phosphodiesterase 2

  2023cites this paper
• The therapeutic potential of targeting cardiac RGS4

  2023cites this paper
• Cyclic GMP and PKG Signaling in Heart Failure

  2022influential citation
• Tuning the Consonance of Microscopic Neuro-Cardiac Interactions Allows the Heart Beats to Play Countless Genres

  2022cites this paper
• Phosphodiesterases and Compartmentation of cAMP and cGMP Signaling in Regulation of Cardiac Contractility in Normal and Failing Hearts

  2022cites this paper
• Cyclic nucleotide phosphodiesterases as therapeutic targets in cardiac hypertrophy and heart failure

  2022cites this paper
• Biosensor-based profiling to track cellular signalling in patient-derived models of dilated cardiomyopathy.

  2022cites this paper
• Compartmentation of cGMP Signaling in Induced Pluripotent Stem Cell Derived Cardiomyocytes during Prolonged Culture

  2022cites this paper
• The natriuretic peptide system in heart failure: Diagnostic and therapeutic implications.

  2021cites this paper
• SCIEN OPEN Silencing miR-370-3p rescues funny current and sinus node function in heart failure

  2021cites this paper
• Compartmentalized cAMP signaling in cardiac ventricular myocytes.

  2021cites this paper
• Upregulation of Phosphodiesterase 2A Augments T Cell Activation by Changing cGMP/cAMP Cross-Talk

  2021cites this paper
• Mechanisms of cAMP compartmentation in cardiac myocytes: experimental and computational approaches to understanding

  2021cites this paper
• Cellular Mechanisms of the Anti-Arrhythmic Effect of Cardiac PDE2 Overexpression

  2021cites this paper
• Cardiac cAMP-PKA Signaling Compartmentalization in Myocardial Infarction

  2021cites this paper
• Bay 60-7550, a PDE2 inhibitor, exerts positive inotropic effect of rat heart by increasing PKA-mediated phosphorylation of phospholamban.

  2021cites this paper
• Mapping genetic changes in the cAMP-signaling cascade in human atria.

  2021cites this paper
• Physiological And Pathological Roles Of Protein Kinase A In The Heart.

  2021cites this paper
• Multifaceted remodelling of cAMP microdomains driven by different aetiologies of heart failure

  2021cites this paper
• Cardiac cGMP signaling in health and disease: location, location, location.

  2020cites this paper
• Multiparametric Mechanistic Profiling of Inotropic Drugs in Adult Human Primary Cardiomyocytes

  2020cites this paper
• An update of cyclic nucleotide phosphodiesterase as a target for cardiac diseases

  2020cites this paper
• Silencing miR-370-3p rescues funny current and sinus node function in heart failure

  2020cites this paper
• The Beta3 Adrenergic Receptor in Healthy and Pathological Cardiovascular Tissues

  2020cites this paper
• Multiplicity of Nitric Oxide and Natriuretic Peptide Signalling in Heart Failure.

  2020cites this paper
• Myocardial Phosphodiesterases and their Role in cGMP Regulation.

  2020cites this paper
• Cyclic nucleotide phosphodiesterases: New targets in the metabolic syndrome?

  2020cites this paper
• Selective changes in cytosolic β-adrenergic cAMP signals and L-type Calcium Channel regulation by Phosphodiesterases during cardiac hypertrophy.

  2020cites this paper
• Therapeutic Implications for PDE2 and cGMP/cAMP Mediated Crosstalk in Cardiovascular Diseases

  2020influential citation
• Cardiac Cyclic Nucleotide Phosphodiesterases: Roles and Therapeutic Potential in Heart Failure

  2020cites this paper
• β3-Adrenoceptor redistribution impairs NO/cGMP/PDE2 signalling in failing cardiomyocytes

  2020cites this paper
• Phosphodiesterase Inhibitors

  2019cites this paper
• The Role of Cyclic AMP Signaling in Cardiac Fibrosis

  2019cites this paper
• PDE5 inhibition improves symptom-free survival and restores transverse tubule loss and catecholamine responsiveness in heart failure

  2019cites this paper
• PDE2 regulates membrane potential, respiration and permeability transition of rodent subsarcolemmal cardiac mitochondria.

  2019cites this paper
• cAMP/PKA signaling compartmentalization in cardiomyocytes: Lessons from FRET-based biosensors.

  2019cites this paper
• The Endocrine Function of the Heart: Physiology and Involvements of Natriuretic Peptides and Cyclic Nucleotide Phosphodiesterases in Heart Failure

  2019cites this paper
• Phosphodiesterase expression in the normal and failing heart.

  2019cites this paper
• Antihypertrophic Effects of Nebivolol on Neonatal Cardiomyocyte Hypertrophy Models

  2019cites this paper
• Phosphodiesterase 2 inhibition preferentially promotes NO/guanylyl cyclase/cGMP signaling to reverse the development of heart failure

  2018influential citation
• Roles of A-Kinase Anchoring Proteins and Phosphodiesterases in the Cardiovascular System

  2018cites this paper
• Critical role of phosphodiesterase 2A in mouse congenital heart defects

  2018cites this paper
• Phosphodiesterase PDE2 activity, increased by isoprenaline, does not reduce β-adrenoceptor-mediated chronotropic and inotropic effects in rat heart

  2018cites this paper
• Imaging of PDE2- and PDE3-Mediated cGMP-to-cAMP Cross-Talk in Cardiomyocytes

  2018cites this paper
• Discovery of novel purine nucleoside derivatives as phosphodiesterase 2 (PDE2) inhibitors: Structure-based virtual screening, optimization and biological evaluation.

  2018cites this paper
• Phosphodiesterase 2A as a therapeutic target to restore cardiac neurotransmission during sympathetic hyperactivity.

  2018cites this paper
• The Development of Compartmentation of cAMP Signaling in Cardiomyocytes: The Role of T-Tubules and Caveolae Microdomains

  2018cites this paper
• Compartmentalized cyclic nucleotides have opposing effects on regulation of hypertrophic phospholipase Cε signaling in cardiac myocytes.

  2018cites this paper
• Acute Enhancement of Cardiac Function by Phosphodiesterase Type 1 Inhibition: Translational Study in the Dog and Rabbit

  2018cites this paper
• Neurocardiac regulation: from cardiac mechanisms to novel therapeutic approaches

  2018cites this paper
• Cyclic AMP signaling in cardiac myocytes

  2018cites this paper
• Phosphodiesterase 5 inhibition improves contractile function and restores transverse tubule loss and catecholamine responsiveness in heart failure

  2018cites this paper
• Voltage-Gated Calcium Channels and Their Roles in Cardiac Electrophysiology

  2018cites this paper
• Role of C-type natriuretic peptide in cardiac structure and function

  2018cites this paper
• Heart failure leads to altered &bgr;2-adrenoceptor/cyclic adenosine monophosphate dynamics in the sarcolemmal phospholemman/Na,K ATPase microdomain

  2018cites this paper
• University of Birmingham Heart failure leads to altered 2-adrenoceptor/cAMP dynamics in the sarcolemmal phospholemman/Na,K ATPase microdomain

  2018cites this paper
• Heart failure leads to altered beta 2-adrenoceptor / cAMP dynamics in the sarcolemmal phospholemman / Na , K ATPase microdomain

  2017cites this paper
• Phosphodiesterase 2 as a Therapeutic Target for Heart Failure: Is Upregulation an Option?

  2017cites this paper
• Nanodomain Regulation of Cardiac Cyclic Nucleotide Signaling by Phosphodiesterases.

  2017cites this paper
• A comprehensive review on the potential therapeutic benefits of phosphodiesterase inhibitors on cardiovascular diseases.

  2017cites this paper
• Phosphodiesterase 2 Protects Against Catecholamine-Induced Arrhythmia and Preserves Contractile Function After Myocardial Infarction

  2017cites this paper
• Mechanisms of the cyclic nucleotide cross-talk signaling network in cardiac L-type calcium channel regulation.

  2017cites this paper
• Microdomains in the Cardiovascular System

  2017cites this paper
• Computational Modeling of Cyclic Nucleotide Signaling Mechanisms in Cardiac Myocytes

  2017cites this paper
• Cyclic GMP/Protein Kinase Localized Signaling and Disease Implications

  2017cites this paper
• Cyclic Nucleotide Phosphodiesterases and Compartmentation in Normal and Diseased Heart

  2017cites this paper
• Cyclic nucleotide imaging and cardiovascular disease.

  2017cites this paper
• PDE2A2 regulates mitochondria morphology and apoptotic cell death via local modulation of cAMP/PKA signalling

  2017cites this paper
• cAMP Compartmentalisation and Hypertrophy of the Heart: ‘Good’ Pools of cAMP and ‘Bad’ Pools of cAMP Coexist in the Same Cardiac Myocyte

  2017cites this paper
• Therapeutic Targeting of PDEs and PI3K in Heart Failure with Preserved Ejection Fraction (HFpEF)

  2017cites this paper
• PDE2 at the crossway between cAMP and cGMP signalling in the heart.

  2017cites this paper
• Old dog, new tricks: novel cardiac targets and stress regulation by protein kinase G.

  2016cites this paper
• Non-coding RNA species in heart failure : regulators of cardiac hypertrophy, fibrosis and inflammation

  2016cites this paper
• Cyclic Nucleotide Regulation of Excitation-Contraction Coupling in Cardiac Myocytes

  2016cites this paper
• Real time cAMP dynamics in the vicinity of phospholemman in healthy and failing cardiomyocytes

  2016cites this paper
• Molecular Physiology of Membrane Guanylyl Cyclase Receptors.

  2016cites this paper
• Phosphodiesterase 2: anti-adrenergic friend or hypertrophic foe in heart disease?

  2016cites this paper
• [Cyclic nucleotide phosphodiesterases: role in the heart and therapeutic perspectives].

  2016cites this paper
• Cardiac Phosphodiesterases and Their Modulation for Treating Heart Disease.

  2016cites this paper
• Genetically Encoded Biosensors Reveal PKA Hyperphosphorylation on the Myofilaments in Rabbit Heart Failure.

  2016cites this paper
• Cyclic nucleotide regulation of cardiac sympatho‐vagal responsiveness

  2016cites this paper